0.0001USD0.00%Mkt Cap: 124 USDP/E: —Last update: 2026-05-25
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatment…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap124 USD
Enterprise Value-1.51M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-12.07M USD
Revenue/Share—
Last Price0.0001 USD
Fiscal Year EndDec 2024
MR QuarterDec 2024
Employees2
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.00
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B-0.00
EPS (TTM)-71.00
EPS (Forward)-0.90
52W Range
0.00010% of range0.4795
52W High0.4795 USD
52W Low0.0001 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE1320.61%
ROA-775.72%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-16.71M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-9887482.26%
Net Debt-1.51M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio0.63
Quick Ratio0.61
Book Value/Sh-1.5340 USD
Cash/Share1.424 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:25
Split DateMar 21, 2025
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.1.24M
Float1.05M
Insiders0.00%
Institutions0.00%
Short Interest
Short Ratio0.0d
Short % Float1.81%
Short % Out.1.81%
Shares Short23.08K
Short (prev mo.)62.88K
Technical
SMA 500.0031 (-96.8%)
SMA 2000.0126 (-99.2%)
Beta2.56
S&P 52W Chg28.31%
Avg Vol (30d)447
Avg Vol (10d)153
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—